0:00 0:00 1x

This is read by an automated voice. Please report any issues or inconsistencies here .

Swiss drugmaker Novartis opened a new 10,000-square-foot manufacturing facility in Carlsbad to make cancer drugs, as part of its promised $23 billion investment push to build out its domestic U.S. facilities over the next five years.

The plant will produce compounds needed for radioligand therapy (RLT), a form of precision medicine that enables the delivery of radiation directly on cancerous tumors while limiting damage to surrounding cells.

“Radioligand therapy is a breakthrough we’ve unlocked at scale, made possible by reimagining how innovation reaches patients,” said Vas Narasimhan, CEO of Novartis. “As the global leader in RLT for more than seven years, we’ve advanced this tec

See Full Page